Binodenoson
Grundinformationen
- CAS
144348-08-3- Standard-SMILES
Nc1nc(N/N=C/C2CCCCC2)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O- InChIKey
XJFMHMFFBSOEPR-DNZQAUTHSA-N- Summenformel
- C17H25N7O4
- Durchschnittliche Molmasse
- 391,4 g/mol
- Monoisotopische Masse
- 391,1968023
Überblick
Binodenoson is a pharmacologic stress agent specific to the only adenosine receptor necessary for increased cardiac blood flow, the A2A receptor. This specificity allows Binodenoson to deliver - in a single injection - a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion.
Namen und Bezeichner
- Bevorzugter Name
- Binodenoson
- IUPAC
- (2R,3R,4S,5R)-2-[6-amino-2-[(2E)-2-(cyclohexylmethylidene)hydrazinyl]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
- Englischer Name
- Binodenoson
- Summenformel
- C17H25N7O4
- Molmasse
- 391.42
Namen und Synonyme
Binodenoson144348-08-3MRE-0470MRE0470WRC-0470CorVueLJA4M1L5LG2-((Cyclohexylmethylene)hydrazino)adenosine(2R,3R,4S,5R)-2-[6-amino-2-[(2E)-2-(cyclohexylmethylidene)hydrazinyl]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diolAdenosine, 2-((cyclohexylmethylene)hydrazino)-2-(Cyclohexylmethylidenehydrazino)adenosineDTXSID60869938
Weitere Namen anzeigen
SHA 211SHA 174MRE 0470BinodisineBinodenoson/MRE-0470Binodenoson, 10 mM in DMSO2-(cyclohexylmethylidenehydrazino)adenos
2-(2-(Cyclohexylmethylene)diazanyl)-9-beta-D-ribofuranosyl-9H-purin-6-aminebinodenosonum(2R,3R,4S,5R)-2-(6-amino-2-((2E)-2-(cyclohexylmethylidene)hydrazinyl)purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol(2R,3R,4S,5R)-2-[6-amino-2-((2E)-2-(cyclohexylmethylidene)hydrazinyl)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diolRefChem:568356DTXCID901509799(2R,3R,4S,5R)-2-(6-amino-2-((E)-2-(cyclohexylmethylidene)hydrazin-1-yl)-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diolWrc 0470
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 1,3
- Polarare Oberfläche (TPSA)
- 164 Ų
- H-Brücken-Donoren
- 5
- H-Brücken-Akzeptoren
- 10
- Frei drehbare Bindungen
- 5
- Schwere Atome
- 28
- Formalladung
- 0
- Komplexität
- 550
Experimentelle und physikochemische Eigenschaften
DrugsPharmaceuticals -> Listed in ZINC15
Physikochemische Eigenschaften
- Schmelzpunkt
- 154 · 154-157°
- Siedepunkt
- 765.6 · 765.6±70.0 °C(Predicted)
- Dichte
- 1.76 · 1.76
- storage temp.
- -20 °C · Store at -20°C
- Löslichkeit
- 125 mg/mL · DMSO : 125 mg/mL (319.35 mM; Need ultrasonic)
- pka
- 6.92 · 6.92±0.70(Predicted)
- Aggregatzustand
- Solid
- Farbe
- White to off-white
- InChIKey
- XJFMHMFFBSOEPR-XNIJJKJLSA-N
- SMILES
- OC[C@H]1O[C@@H](N2C3C(=C(N=C(NN=CC4CCCCC4)N=3)N)N=C2)[C@H](O)[C@@H]1O
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Sicherheitsdaten
- Alarmwort
- Achtung
- Gefahrenhinweise
- Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code H302
Chemie und Industrie
Pharmakologische Informationen
PharmacodynamicsBinodenoson, a novel cardiovascular disease diagnostic, is a adenosine A2A receptor agonist in development for cardiac pharmacologic stress SPECT imaging, which is used to diagnose coronary artery disease.
Mechanism of Action
Binodenoson is a highly selective adenosine A2A receptor agonist. The adenosine A2A receptor is necessary for increased cardiac blood flow, and specificity to this particular receptor allows binodenoson to deliver, in a single injection, a more effective dose of medication with fewer side effects than current treatments, which typically require a 15-20 minute infusion. Cardiac stress tests allow physicians to identify the presence of cardiovascular disease by examining the flow of blood through the heart.
Biological Half-Life10 ± 4 minutes
MeSH Pharmacological ClassificationCompounds that bind to and stimulate PURINERGIC P1 RECEPTORS.
Anwendungen
BeschreibungBinodenoson, 2-[(cyclohexylmethylene)hydrazino] adenosine (MRE0470), is being developed as a short-acting coronary vasodilator, administered intravenously, as an adjunct to radiotracers in myocardial stress imaging techniques to detect the presence and severity of CAD in patients unable to exercise. The compound is a highly selective agonist at the adenosine A2A receptor and also has a weaker affinity for adenosine A1-, A2B-, and A3-receptor subtypes than adenosine[1].
Verwenden2-(cyclohexylmethylidenehydrazino)adenosine is used in the diagnosis of coronary heart disease (adenosine A2A agonist).
Anbieter
Wird geladen…
Öffentliche Anfragen
Wird geladen…
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…